QRSKIN's wound dressings help severly damaged skin to achieve fast tissue regeneration and become functional again.

R&D Programs

QRSKIN GmbH works on a number of R&D projects in close collaboration with its affiliated company EVOMEDIS GmbH located in Graz (Austria). The R&D programs focus on the development of innovative solutions for the treatment of critical wounds. We work on further improvements of the epicitehydro wound dressing material as well as on line extensions of epicitehydro for new indications.

In addition we are developing an allogeneic cell therapy based on a new keratinocyte product for the treatment of deep 2b burns and the potential option to treat sever ulcers.